Benzo thiadiazine matrix metalloproteinase inhibitors
    11.
    发明授权
    Benzo thiadiazine matrix metalloproteinase inhibitors 失效
    苯并噻二嗪基质金属蛋白酶抑制剂

    公开(公告)号:US06656932B2

    公开(公告)日:2003-12-02

    申请号:US10074646

    申请日:2002-02-13

    IPC分类号: C07D28522

    摘要: Selective MMP-13 inhibitors are benzo thiadiazines of the Formula or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or alkyl; R1 and R3 include hydrogen, alkyl, and aryl, with the proviso that R3 is not (CH2)m biphenyl or (CH2)m substituted biphenyl; X is O or NH, n is 0, 1, or 2. The compounds of Formula I, or a pharmaceutically acceptable salt thereof, is useful for treating diseases mediated by an MMP-13 enzyme, including diseases selected from osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure.

    摘要翻译: 选择性MMP-13抑制剂是其配制剂的药学上可接受的盐的苯并噻二嗪,其中R 2是氢或烷基; R 1和R 3包括氢,烷基和芳基,条件是R 3不是(CH 2)m联苯基或(CH 2)m取代的联苯基; X是O或NH,n是0,1或2.式I化合物或其药学上可接受的盐可用于治疗由MMP-13酶介导的疾病,包括选自骨关节炎,类风湿性关节炎, 癌症,炎症和心力衰竭。